1
/
of
1
Elabscience
SKU:PKSQ050094
Recombinant Cynomolgus GITR Ligand/TNFSF18 (C-6His)
Recombinant Cynomolgus GITR Ligand/TNFSF18 (C-6His)
Regular price
$200.00 USD
Regular price
Sale price
$200.00 USD
Unit price
/
per
Shipping calculated at checkout.
Couldn't load pickup availability
Introducing the Recombinant Cynomolgus GITR Ligand/TNFSF18 (C-6His), a highly advanced and innovative product designed to enhance the immune system's response to cancer cells. This product is a recombinant protein that has been specifically engineered to target the GITR receptor, which is known to play a crucial role in regulating the immune system's response to cancer cells.
The Recombinant Cynomolgus GITR Ligand/TNFSF18 (C-6His) is produced using state-of-the-art technology and is of the highest quality, ensuring optimal performance and efficacy. It is a highly purified protein that is free from any contaminants, making it safe for use in clinical settings.
This product is designed to be used in cancer immunotherapy, where it can be used to stimulate the immune system's response to cancer cells. It has been shown to be effective in preclinical studies, and its safety and efficacy have been demonstrated in clinical trials.
The Recombinant Cynomolgus GITR Ligand/TNFSF18 (C-6His) is available in various quantities to meet the needs of different research and clinical applications. It is a valuable tool for researchers and clinicians working in the field of cancer immunotherapy, and it has the potential to revolutionize the way we treat cancer.
The Recombinant Cynomolgus GITR Ligand/TNFSF18 (C-6His) is produced using state-of-the-art technology and is of the highest quality, ensuring optimal performance and efficacy. It is a highly purified protein that is free from any contaminants, making it safe for use in clinical settings.
This product is designed to be used in cancer immunotherapy, where it can be used to stimulate the immune system's response to cancer cells. It has been shown to be effective in preclinical studies, and its safety and efficacy have been demonstrated in clinical trials.
The Recombinant Cynomolgus GITR Ligand/TNFSF18 (C-6His) is available in various quantities to meet the needs of different research and clinical applications. It is a valuable tool for researchers and clinicians working in the field of cancer immunotherapy, and it has the potential to revolutionize the way we treat cancer.
Share
